期刊
MOVEMENT DISORDERS CLINICAL PRACTICE
卷 9, 期 6, 页码 751-758出版社
WILEY
DOI: 10.1002/mdc3.13471
关键词
cannabinoids; nabilone; sleep problems; Parkinson's disease; non-motor symptoms
资金
- AOP Orphan Pharmaceuticals AG
- Clinical Trial Centre of the Medical University of Innsbruck
Nabilone may have beneficial effects on sleep outcomes in Parkinson's disease patients with sleep problems.
Background The synthetic tetrahydrocannabinol analogue nabilone improved overall non-motor symptom (NMS) burden in Parkinson's disease (PD) patients in comparison to placebo. Objectives To characterize the effects of nabilone on different sleep outcomes in PD patients. Methods We performed a post-hoc analysis of the controlled, double-blind, enriched enrollment randomized withdrawal NMS-Nab study to assess the effects of nabilone on sleep outcomes in study participants who reported clinically-relevant sleep problems (MDS-UPDRS-1.7 >= 2 points). Results After open-label nabilone administration, 77.4% reported no relevant sleep problem. In the withdrawal phase of the trial, the MDS-UPDRS-1.7. and the NMS-Scale Domain 2 (i.e., Sleep/Fatigue) significantly worsened only in PD patients in the placebo group, which was mostly driven by a significant worsening of insomnia (question 5 of the NMS-Scale Domain 2). Conclusions This post-hoc analysis of the NMS-Nab trial suggests that nabilone has beneficial effects on sleep outcomes in PD patients experiencing sleep problems at baseline. The original trial was registered with (NCT03769896, ) and EudraCT (2017-000192-86).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据